---
title: "Odyssey Therapeutics, Inc. (ODTX.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ODTX.US.md"
symbol: "ODTX.US"
name: "Odyssey Therapeutics, Inc."
industry: "Biotechnology"
datetime: "2026-05-16T02:59:05.634Z"
locales:
  - [en](https://longbridge.com/en/quote/ODTX.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ODTX.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ODTX.US.md)
---

# Odyssey Therapeutics, Inc. (ODTX.US)

## Company Overview

Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic inflammatory responses activation of interferon regulatory factor 5 (IRF5); OD-003, a protein therapeutic designed to agonize tumor necrosis factor receptor 2 selectively on Treg; a TSLP/IL-33 bispecific antagonist; an oral small molecule interleukin-1 receptor–associated kinase 4 scaffolding inhibitor; and a small molecule inhibitor of IRF5. The company was incorporated in 2021 and is headquartered in Boston, Massachusetts.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [odysseytx.com](https://odysseytx.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-15T04:30:13.000Z

**Overall: C (0.59)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 116 / 390 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -33.45% |  |
| Net Profit YoY | -13.99% |  |
| P/B Ratio | -1.68 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 818452599.08 |  |
| Revenue | 2976000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 34.14% | A |
| Profit Margin | -4994.86% | E |
| Gross Margin | -3971.77% | E |
| Revenue YoY | -33.45% | E |
| Net Profit YoY | -13.99% | D |
| Total Assets YoY | 36.65% | A |
| Net Assets YoY | 62.59% | A |
| Cash Flow Margin | 87.10% | C |
| OCF YoY | -33.45% | E |
| Turnover | 0.01 | E |
| Gearing Ratio | 20.20% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Odyssey Therapeutics, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-33.45%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-13.99%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "-1.68",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "818452599.08",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "2976000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "34.14%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "-4994.86%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "-3971.77%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "-33.45%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-13.99%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "36.65%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "62.59%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "87.10%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "-33.45%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.01",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "20.20%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -5.60 | 388/390 | - | - | - |
| PB | -1.71 | 491/390 | - | - | - |
| PS (TTM) | 279.78 | 279/390 | - | - | - |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/ODTX.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/ODTX.US/norm.md)
- [Related News](https://longbridge.com/en/quote/ODTX.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/ODTX.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**